Markets:

Overview

News

Currencies

International

Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

37.61 +1.40 (+3.87%)

Streaming Delayed Price Updated: 11:10 AM EDT, Jun 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Edgewise Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

September 19, 2024

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

September 17, 2024

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics: Q4 Earnings Insights ↗

February 22, 2024

Via Benzinga

How Is The Market Feeling About Edgewise Therapeutics? ↗

January 31, 2024

Via Benzinga

EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q2 2024 ↗

August 08, 2024

EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

August 08, 2024

From Edgewise Therapeutics

Via Business Wire

7 Small-Cap Stocks to Buy for Large-Scale Gains ↗

July 30, 2024

Although small-cap stocks are incredibly risky, their underappreciated nature potentially gives them a high performance ceiling.

Via InvestorPlace

Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs ↗

July 23, 2024

What sectors outperformed after Trump won the 2016 election, and which outperformed during his term?

Via Investor's Business Daily

Topics Government

Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense ↗

July 16, 2024

Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.

Via Investor's Business Daily

Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day ↗

May 13, 2024

The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM.

Via Investor's Business Daily

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024

May 10, 2024

From Edgewise Therapeutics

Via Business Wire

EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024 ↗

May 09, 2024

EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2 ↗

May 09, 2024

Via Benzinga

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 09, 2024

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

May 07, 2024

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)

May 06, 2024

From Edgewise Therapeutics

Via Business Wire

Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies

April 23, 2024

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)

April 15, 2024

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session

March 28, 2024

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024

March 27, 2024

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024

March 05, 2024

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

February 28, 2024

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

February 22, 2024

From Edgewise Therapeutics

Via Business Wire

Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)

February 13, 2024

From Edgewise Therapeutics

Via Business Wire

Insider Favorites: 7 Stocks with Bullish Buying Signals ↗

February 11, 2024

Although you’ll still want to conduct your due diligence, following the smart money into these insider favorite stocks is tempting.

Via InvestorPlace

Insiders Buying Edgewise Therapeutics And 2 Other Stocks ↗

January 26, 2024

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

January 19, 2024

Via Benzinga

Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

January 19, 2024

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode...

Via Benzinga

What's Going On With Edgewise Therapeutics Stock? ↗

January 19, 2024

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) shares are trading higher Friday after the company announced the pricing of its $240 million underwritten offering of 21,818,182 shares at $11 per share.

Via Benzinga

World Acceptance Posts Upbeat Earnings, Joins Kaman, Spirit Airlines And Other Big Stocks Moving Higher On Friday ↗

January 19, 2024

U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of World Acceptance Corporation (NASDAQ: WRLD) rose sharply during Friday’s session following upbeat...

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.